Additionally, investigating the impact of ALKBH5 activity on the response of CML cells to current therapies or its influence on leukemia development could shed light on its potential role in the disease process. The gene discussed is ALKBH5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.